Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma by Seema Chugh, Jean C. Tien, Jennifer Hon, Carson Kenum, Rahul Mannan, Yunhui Cheng, Chi Chiang Li, Zainab I. Taher, Andrew D. Delekta, Pushpinder Singh Bawa, Ingrid J. Apel, Stephanie J. Miner, Xuhong Cao, Rohit Mehra, Saravana M. Dhanasekaran, Yuanyuan Qiao, Rajen Mody, Arul M. Chinnaiyan

Subjects: Get full text

Wilms tumor primary cultures capture phenotypic heterogeneity and facilitate preclinical screening by Lisa Götz, Jenny Wegert, Alireza Paikari, Silke Appenzeller, Sabrina Bausenwein, Christian Vokuhl, Taryn D. Treger, Jarno Drost, Christin Linderkamp, Dominik T. Schneider, Karen Ernestus, Steven W. Warman, Jörg Fuchs, Nils Welter, Norbert Graf, Sam Behjati, Rhoikos Furtwängler, Manfred Gessler

Subjects: Get full text

Heat shock transcription factor 1 facilitates liver cancer progression by driving super‐enhancer‐mediated transcription of MYCN by Yizhe Liu, Qili Shi, Yue Su, Zhiao Chen, Xianghuo He

Subjects: Get full text

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy by Laura Grunewald, Lena Andersch, Konstantin Helmsauer, Silke Schwiebert, Anika Klaus, Anton G. Henssen, Teresa Straka, Marco Lodrini, Sebastian G. Wicha, Steffen Fuchs, Falk Hertwig, Frank Westermann, Alice Vitali, Carlotta Caramel, Gabriele Büchel, Martin Eilers, Kathy Astrahantseff, Angelika Eggert, Uta E. Höpken, Johannes H. Schulte, Thomas Blankenstein, Kathleen Anders, Annette Künkele

Subjects: Get full text